August 20, 2026 | Havas Lynx, Point.1
The traditional model for gathering insights is reaching a breaking point. Healthcare Professionals (HCPs) are increasingly time-poor and difficult to reach. Simultaneously, the costs of traditional market research are rising, while the compressed timelines of global launch cycles demand faster results than ever. We are caught in a paradox: the pressure to accelerate our decision-making is clashing with the absolute necessity for deep, actionable customer understanding.

This is why synthetic testing is not just a trend, it’s a strategic imperative.
Point.1’s SensAI is built for Pharma, by Pharma. Our synthetic personas are not generic; they’re constructed from the industry’s most robust comms-based HCP dataset: 11,000+ professionals across 8+ geographies and 10+ therapy areas, with 2,500+ variables per respondent.
And we go further. SensAI integrates Lexicon analysis to identify critical knowledge gaps, hundreds of award-winning case studies to establish “best-in-class” benchmarks, and competitor norms to ensure true brand differentiation. By aligning this data with behavioural science, we create a 360-degree view that transforms raw data into strategic creative scoring.
The common scepticism surrounding synthetic testing is: Can it really replace human insight? We put that question to the test by running a head-to-head comparison with traditional human quantitative research.
The results were statistically compelling. Our synthetic testing achieved an 86% predictive match with human benchmarks, with correlation of R=0.93 for PCPs and R=0.84 for Neurologists.

The figures prove that our AI doesn’t just mimic human responses; it mirrors them with high statistical confidence, allowing teams to down-select concepts with rigorous evidence.
To be clear: synthetic testing is a guide, not a replacement for human judgment. AI is an algorithm, and its value is defined by its foundational architecture. However, when deployed within a testing framework, it allows teams to iterate at speed, killing “dead-on-arrival” concepts before they consume precious human research budgets. It’s about making smarter decisions: 40% faster and significantly cheaper.
Why choose SensAI? Because our dataset is built with Pharma marcomms objectives at its heart. We don’t just understand the HCP’s professional background; we understand their personal drivers, their content preferences, and the specific touchpoints where they engage.
As we move toward a future of faster launches and tighter budgets, the brands that win will be those that use synthetic personas to de-risk their strategy early. The future of decisioning is here, and it is built on robust, data-driven confidence.
This content was provided by Havas Lynx
Company Details
Latest Content from Havas Lynx
Better for patients, better for business
Our point of view
The case to embrace going social
Today, we’re focussed on getting to know our new target: she’s online, mobile, and connected to a large network of friends, information, and marketers who help her make decisions about…
